Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Deletion of the FOXO1 Gene Transforms Intestinal Cells into Insulin Producers

By BiotechDaily International staff writers
Posted on 13 Jul 2014
Image: Human gastrointestinal cells from patients were engineered to express insulin (fluorescent green) in the laboratory (Photo courtesy of Columbia University).
Image: Human gastrointestinal cells from patients were engineered to express insulin (fluorescent green) in the laboratory (Photo courtesy of Columbia University).
After having demonstrated that gut endocrine progenitor cells of mice could be differentiated into glucose-responsive, insulin-producing cells by elimination of the transcription factor FOXO1 (forkhead box O1), diabetes researchers have extended these findings by obtaining similar results with human gut endocrine progenitor and serotonin-producing cells.

Generation of alternative sources of insulin-producing beta-cells has been a goal of researchers in the field of diabetes therapy. While most efforts have been directed at differentiating embryonic or induced pluripotent stem (iPS) cells into beta-like-cells, investigators at Columbia University (New York, NY, USA) have shown that shown that mouse intestinal cells could be transformed into insulin-producing cells by deactivating the cells’ FOXO1 gene.

In a paper published in the June 30, 2014, online edition of the journal Nature Communications, the investigators revealed that FOXO1 was present in human gut endocrine progenitor and serotonin-producing cells. Using gut organoids derived from human iPS cells, they demonstrated that inhibition of FOXO1 using a dominant-negative mutant or Lentivirus-encoded small hairpin RNA promoted generation of insulin-positive cells that expressed all markers of mature pancreatic beta-cells and survived in vivo following transplantation into mice.

“People have been talking about turning one cell into another for a long time, but until now we had not gotten to the point of creating a fully functional insulin-producing cell by the manipulation of a single target,” said senior author Dr. Domenico Accili, professor of diabetes at Columbia University. “By showing that human cells can respond in the same way as mouse cells, we have cleared a main hurdle and can now move forward to try to make this treatment a reality.”

Related Links:

Columbia University



Channels

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.